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Objective: To study the inhibiting effect of Endostar combined with ginsenoside Rg3 on
breast cancer tumor growth in tumor-bearing mice.
Methods: Female mice were selected as experimental animals, and breast cancer tumor-
bearing mouse models were established and then divided into groups A, B, C and D that
respectively received saline, recombinant human endostatin, ginsenosides Rg3 and re-
combinant human endostatin combined with Rg3 intervention; 7 d, 14 d and 21 d after
intervention, tumor tissue volume was measured; 21 d after intervention, mice were
killed, tumor tissue was collected, and mRNA contents of angiogenesis molecules, in-
vasion molecules, autophagy marker molecules and autophagy signaling pathway mol-
ecules were detected.
Results: At 7 d, 14 d and 21 d after intervention, tumor tissue volume of groups B, C and
D was lower than that of group A, and tumor tissue volume of group D was lower than
that of groups B and C; mRNA contents of VEGFA, VEGFB, VEGFC, MMP2, MMP9,
p62, mTOR, PI3K, Akt, JNK and Beclin-1 in tumor tissue of groups B, C and D were
signiﬁcantly lower than those of group A, and LC3-II/LC3-I was signiﬁcantly higher than
that of group A; mRNA contents of VEGFA, VEGFB, VEGFC, MMP2, MMP9, p62,
mTOR, PI3K, Akt, JNK and Beclin-1 in tumor tissue of group D were signiﬁcantly lower
than those of groups B and C, and LC3-II/LC3-I was higher than that of groups B and C.
Conclusions: Endostar combined with ginsenoside Rg3 has stronger inhibiting effect on
breast cancer tumor growth in tumor-bearing mice than single drug, and it can inhibit
angiogenesis and cell invasion, and enhance cell autophagy.1. Introduction
Breast cancer is the malignant tumor with highest incidence
in women, and its incidence increases in recent years. Cancer
cell proliferation, invasion and local angiogenesis are the ma-
lignant biological behaviors closely related to the occurrence and
development of breast cancer. Regulation of malignant biolog-
ical behaviors of tumors is a process involving multiple targets
and multiple genes, and simultaneous use of drugs against
different targets can more effectively inhibit the development ofmalignant tumors. Recombinant human endostatin (Endostar) is
a kind of targeted drug with anti-angiogenesis effect, and gin-
senoside Rg3 is an important component with effect of inhibit-
ing cell proliferation and invasion [1,2]. The two drugs can target
different links of malignant biological effect and exert antitumor
effect, and are expected to be able to achieve synergistic and
additive effect. In the following research, the inhibiting effect
of Endostar combined with ginsenoside Rg3 on breast cancer
tumor growth in tumor-bearing mice was analyzed.
2. Materials and methods
2.1. Experimental materials
A total of 32 Female C57 mice were purchased from Shan-
dong University Laboratory Animal Center; breast cancer MCF-
7 cell lines were purchased from the cell bank of Chinesele under the CC BY-NC-ND license (http://
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was purchased from Shandong Simcere Medgenn Biological
Pharmaceutical Co., Ltd.; ginsenoside Rg3 was purchased from
Liaoning Bio-medical Technology Co., Ltd., and RNA extrac-
tion as well as PCR ampliﬁcation kits were purchased from
Beijing ComWin Company.
2.2. Experimental methods
2.2.1. Establishment of tumor-bearing mouse models
MCF-7 cell lines were recovered and cultured with RPMI-
1640 media that contained 10% fetal bovine serum, 100 IU/
mL penicillin and 100 IU/mL streptomycin; after 2–3 sub-
cultures, cells that were digested with pancreatin were collected,
density was adjusted to 5 × 107 mL and 0.1 mL of cells were
inoculated under right mammary gland; 2–3 wk after inocula-
tion, tumor volume grew to 150–200 mm3, and mice were used
for subsequent study and randomly divided into groups A–D,
each group with 8 mice.
2.2.2. Medication of tumor-bearing mice
Group A received intraperitoneal injection of same volume of
saline as groups B–D; group B received subcutaneous injection
of 10 mg/kg recombinant human endostatin, 1 time/2 d; group C
received subcutaneous injection of 5 mg/kg ginsenoside Rg3,
1 time/2 d; group D received subcutaneous injection of 10 mg/
kg recombinant human endostatin and 5 mg/kg ginsenoside
Rg3. Medication was 10 times in a row.
2.2.3. Measurement of tumor volume
At 7 d, 14 d and 21 d after medication, major diameters and
minor diameters of tumor tissue of four groups were measured,
and the following formula was used to calculate tumor volume:
volume = major diameter × minor diameter2 × 0.5.
2.2.4. Collection of tumor tissue and detection of related
indexes
At 21 d after medication, tumor-bearing mice were killed
after measurement of tumor volume was completed; tumor tissue
was collected, washed with saline and then rapidly frozen with
liquid nitrogen; then RNA extraction kits were used to obtain
RNA in the tissue and reverse-transcribe it to cDNA for PCR
reaction, and ampliﬁed genes included vascular endothelial
growth factor (VEGF)A, VEGFB, VEGFC, matrix metal-
loproteinase (MMP)2, MMP9, LC3-II, LC3-I, p63, mTOR,
PI3K, Akt, JNK and Beclin-1. Ampliﬁcation curve was obtained,
and then mRNA contents of related genes in tumor tissue of
group A were set to 100 to calculate relative values of mRNA
contents of corresponding genes in tumor tissue of groups B, CTable 1
Trend of tumor tissue volume of four groups (mm3).
Group Before intervention 7 d After intervention
Group A 158.52 ± 16.15 314.36 ± 36.78
Group B 160.23 ± 15.38a 244.44 ± 24.34a
Group C 157.39 ± 12.92a 250.34 ± 27.42a
Group D 161.29 ± 17.88a,b,c 194.28 ± 22.14a,b,c
F 0.182 6.967
P >0.05 <0.05
Compared with group A, aP < 0.05; compared with group B, bP < 0.05; coand D. Mice were killed and incinerated together after materials
were collected.
2.3. Statistical process
SPSS18.0 software was used to input above data, measure-
ment data of four groups were processed by variance analysis
and P < 0.05 was standard of statistical signiﬁcance in
differences.
3. Results
3.1. Trend of tumor tissue volume
At 21 d after intervention, tumor tissue volume of four
groups showed increasing trend, increasing trend of tumor tissue
volume of groups B, C and D was weaker than that of group A,
and increasing trend of tumor tissue volume of group D was
weaker than that of groups B and C; tumor tissue volume of
groups B, C and D at various points in time was lower than that
of group A, and tumor tissue volume of group D was lower than
that of groups B and C (Table 1).
3.2. Expression levels of VEGFs and MMPs molecules
in tumor tissue
Expression levels of VEGFA, VEGFB and VEGFC as well as
MMP2 and MMP9 in tumor tissue of groups B, C and D were
signiﬁcantly lower than those of group A; expression levels of
VEGFA, VEGFB and VEGFC as well as MMP2 and MMP9 in
tumor tissue of group D were signiﬁcantly lower than those of
groups B and C (Table 2).
3.3. Expression levels of autophagy marker molecules
LC3-II/LC3-I in tumor tissue of groups B, C and D was
higher than that of group A, and mRNA contents of p62 were
signiﬁcantly lower than that of group A; LC3-II/LC3-I in tumor
tissue of group D was higher than that of groups B and C, and
mRNA content of p62 was lower than those of groups B and C
(Table 3).
3.4. Autophagy signaling pathway function
mRNA contents of mTOR, PI3K, Akt, JNK and Beclin-1 in
tumor tissue of groups B, C and D were lower than those of
group A, and mRNA contents of mTOR, PI3K, Akt, JNK and
Beclin-1 in tumor tissue of group D were lower than those of
groups B and C (Table 4).14 d After intervention 21 d After intervention
498.37 ± 51.28 723.67 ± 81.51
333.63 ± 37.55a 485.29 ± 61.17a
338.57 ± 35.34a 492.33 ± 47.22a
257.35 ± 27.14a,b,c 337.28 ± 42.78a,b,c
8.485 11.339
<0.05 <0.05
mpared with group C, cP < 0.05.
Table 2
Expression levels of VEGF and MMPs molecules in tumor tissue of four groups.
Group mRNA contents of VEGFs mRNA contents of MMPs
VEGFA VEGFB VEGFC MMP2 MMP9
Group A 100.00 ± 12.58 100.00 ± 15.10 100.00 ± 13.16 100.00 ± 11.48 100.00 ± 13.22
Group B 68.18 ± 7.37a 63.51 ± 7.24a 70.36 ± 8.17a 52.15 ± 6.32a 57.41 ± 6.23a
Group C 71.67 ± 7.11a 68.24 ± 6.91a 72.73 ± 7.78a 53.73 ± 6.75a 61.27 ± 7.35a
Group D 28.41 ± 2.95a,b,c 19.33 ± 2.14a,b,c 39.22 ± 4.28a,b,c 22.36 ± 3.95a,b,c 15.33 ± 1.86a,b,c
F 18.948 26.844 15.482 20.183 17.785
P <0.05 <0.05 <0.05 <0.05 <0.05
Compared with group A, aP < 0.05; compared with group B, bP < 0.05; compared with group C, cP < 0.05.
Table 3
Expression levels of autophagy marker molecules in tumor tissue of four groups.
Group LC3-II/LC3-I p62
Group A 1.00 ± 0.11 100.00 ± 12.91
Group B 1.89 ± 0.13a 53.42 ± 6.31a
Group C 1.77 ± 0.20a 55.38 ± 5.72a
Group D 3.23 ± 0.38a,b,c 27.37 ± 3.12a,b,c
F 14.922 22.108
P <0.05 <0.05
Compared with group A, aP < 0.05; compared with group B, bP < 0.05; compared with group C, cP < 0.05.
Table 4
Expression levels of autophagy signaling pathway-related molecules in tumor tissue of four groups.
Group mTOR/PI3K/Akt JNK/Beclin-1
mTOR PI3K Akt JNK Beclin-1
Group A 100.00 ± 12.78 100.00 ± 15.91 100.00 ± 13.18 100.00 ± 15.47 100.00 ± 13.48
Group B 58.95 ± 7.12a 63.94 ± 7.22a 61.35 ± 6.94a 82.26 ± 9.14a 55.68 ± 5.84a
Group C 62.28 ± 6.88a 66.20 ± 6.96a 60.17 ± 5.35a 77.33 ± 7.97a 58.15 ± 6.24a
Group D 35.22 ± 4.12a,b,c 21.39 ± 3.25a,b,c 16.36 ± 1.82a,b,c 26.43 ± 2.89a,b,c 34.24 ± 4.12a,b,c
F 17.877 24.961 33.812 21.305 20.184
P <0.05 <0.05 <0.05 <0.05 <0.05
Compared with group A, aP < 0.05; compared with group B, bP < 0.05; compared with group C, cP < 0.05.
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Recombinant human endostatin (Endostar) is endostatin that
is independently developed by Chinese scientists and it has anti-
angiogenesis effect [3]. The drug uses Escherichia coli as
expression vector to obtain the desired proteins, the expression
efﬁciency is high, physicochemical properties are stable, and
the drug itself has lower toxicity and less adverse reaction [4].
Study has conﬁrmed that application of the drug can inhibit
the progression and pathological process of breast cancer, and
reduce the expression of pro-angiogenesis molecules and pro-
invasion molecules [5]. In the research, after breast cancer
tumor-bearing mouse models were established, recombinant
human endostatin was used for intervention, and then dynamic
changes of tumor volume were measured. Analysis results
showed that increasing trend of breast cancer tumor tissue vol-
ume of group B was signiﬁcantly weaker than that of group A,
and 7 d, 14 d and 21 d after intervention, breast cancer tumor
tissue volume of group B was signiﬁcantly lower than that of
group A. It indicated that recombinant human endostatin could
inhibit breast cancer tumor growth in tumor-bearing mice.
Ginsenoside Rg3 is a kind of antitumor composition
extracted from extracting solution of ginseng root, and it has
inhibiting effect on biological behaviors of a variety of malig-
nant tumor cells [6]. Studies have conﬁrmed that antitumor
activity of ginsenoside Rg3 is manifested as inhibiting cancercell proliferation, invasion and angiogenesis, and molecules
that are inhibited include cyclin, vascular endothelial growth
factor, matrix metalloproteinase and so on [7,8]. In the
research, after breast cancer tumor-bearing mouse models were
established, ginsenoside Rg3 was used for intervention, and then
dynamic changes of tumor volume were measured. Analysis
results showed that increasing trend of breast cancer tumor tissue
volume of group C was signiﬁcantly weaker than that of group
A, and 7 d, 14 d and 21 d after intervention, breast cancer tumor
tissue volume of group C was signiﬁcantly lower than that of
group A. It indicated that ginsenoside Rg3 could inhibit the
breast cancer tumor growth in tumor-bearing mice.
In the development process of breast cancer, malignant bio-
logical behaviors of cancer cells are regulated by a variety of
molecules, and combined application of drugs with different
mechanisms can block different links of malignant biological
behaviors, thereby more effectively inhibiting the development
of tumor. Ginsenoside Rg3 and recombinant human endostatin
can act on different links of malignant biological behaviors of
breast cancer cells, and combined application of the two drugs is
expected to be able to more effectively inhibit the development
of breast cancer. In the research, tumor tissue volume of four
groups was compared, and ﬁrst of all, breast cancer tumor tissue
volume of group D was signiﬁcantly lower than that of group A,
which indicated that ginsenoside Rg3 combined with recombi-
nant human endostatin could inhibit breast cancer growth;
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signiﬁcantly lower than that of groups B and C, which indicated
that ginsenoside Rg3 combined with recombinant human
endostatin had stronger inhibiting effect on breast cancer growth
than single drug.
Local angiogenesis and cell inﬁltration are the basis of the
occurrence and development of tumor, and formation of new
blood vessels in tumor tissue as well as inﬁltration of cancer
cells to vascular structure can provide blood supply to the
metabolism of tumor cells, meanwhile reduce resistance of
vascular system and increase blood ﬂow and blood supply.
Tumor angiogenesis is a complex process involving a variety of
cytokines, including the links of pro-angiogenesis factor
enhancement, cell adhesion and invasion to endothelial base-
ment membrane and formation of vascular structure. VEGF is
the currently known cytokine with the strongest pro-
angiogenesis effect, and it can speciﬁcally act on endothelial
cells and promote the formation of vascular structure [9,10];
MMPs are molecules directly related to the degradation of
extracellular matrix and basement membrane components, and
they can promote cancer cell invasion to vascular system as
well as reduce vascular resistance and increase tumor blood
supply [11,12]. In the research, after tumor-bearing mice
received combined treatment of recombinant human endostatin
and ginsenoside Rg3, expression levels of above molecules in
tumor tissue were analyzed, and results showed that expression
levels of VEGFA, VEGFB and VEGFC as well as MMP2 and
MMP9 in tumor tissue of groups B, C and D were lower than
those of group A and expression levels of above molecules of
group D were lower than those of groups B and C. It indicated
that both recombinant human endostatin and ginsenoside Rg3
could inhibit the expression of VEGFs and MMPs, combined
application of the two drugs had synergistic effect and the
inhibiting effect was more signiﬁcant.
Study in recent years believes that cell autophagy is related to
the occurrence and development of malignant tumors. Auto-
phagy means that cells use lysosomes to degrade damaged or-
ganelles and macromolecular substances, and it can cause cell
death. The process is another type of programmed cell death
different from apoptosis and necrosis, also known as ‘Type II
cell death’. Activating autophagy process can induce cell
apoptosis, and therefore, autophagy has also become a new
target for treatment of malignant tumors [13]. LC3 and P62 are
autophagy marker molecules, and in the process of autophagy,
LC3-I transforms to LC3-II and ubiquitin protein p62 is
degraded [14]. In the research, analysis of the expression levels of
autophagy marker molecules showed that LC3-II/LC3-I in tumor
tissue of groups B, C and D was higher than that of group A and
mRNA contents of p62 were lower than that of group A; LC3-II/
LC3-I in tumor tissue of group D was higher than that of groups
B and C and mRNA content of p62 was lower than those of
groups B and C. It indicated that both recombinant human
endostatin and ginsenoside Rg3 could enhance cell autophagy
and the enhancement effect of combined use of the two drugs
was more signiﬁcant. mTOR/PI3K/Akt and JNK/Beclin-1 are
currently known two signaling pathways that regulate autophagy
process, and enhancement of their function can inhibit cell
autophagy and create an enabling environment for cell prolif-
eration. In the research, analysis of the function of two signaling
pathways in tumor tissue showed that both recombinant human
endostatin and ginsenoside Rg3 could inhibit the function ofmTOR/PI3K/Akt and JNK/Beclin-1 signaling pathways and thus
enhance cell autophagy process, and the inhibiting effect of
combined use of the two drugs was stronger.
Based on above discussion, it can be concluded that Endostar
combined with ginsenoside Rg3 has stronger inhibiting effect on
breast cancer tumor growth in tumor-bearing mice than single
drug, and it can inhibit angiogenesis and cell invasion, and
enhance cell autophagy.
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